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Lenalidomide is an immunomodulatory drug with therapeutic activity in chronic lymphocytic leukemia (CLL). However, it has
pleiotropic effects, and the mechanism of action responsible for its therapeutic activity has not been well defined yet. Herein, we
show that lenalidomide treatment does not have an effect on the proliferation of leukemia cells, but it increases the proliferation of B
cells from healthy donors. Lenalidomide did not exert a direct effect on the apoptosis of leukemia cells obtained from CLL patients,
although it indirectly induced their apoptosis through the activation of nonmalignant immune cells. Thus, lenalidomide markedly
increased the proliferation of NK and CD4 T cells. The effect of lenalidomide on NK cells was secondary to the induction of IL-2
production by CD4 T cells. Accordingly, depletion of T cells or blockade of IL-2 activity completely abrogated the proliferation
of NK cells. Additionally, lenalidomide enhanced NK and NKT-like cell-mediated natural cytotoxicity against leukemia cells from
CLL patients. Lenalidomide also upregulated CD20 expression on leukemia cells and, accordingly, it had a synergistic effect with
rituximab on promoting antibody-dependent cell-mediated cytotoxicity against primary leukemia cells. Overall, these observations
provide a support for combining lenalidomide with rituximab as a treatment in CLL.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous
disease, with a clinical presentation ranging from indolent
to advanced stage disease. A therapeutic intervention is
scarcely required in patients with indolent disease, whereas
chemotherapy treatment is frequently required in patients
with advanced stage disease. However, CLL is generally
considered as an incurable disease and, consequently, the
development of new therapeutic strategies is a key goal in this
malignancy [1].
Increasing evidence demonstrates that the tumor mi-
croenvironment plays a critical role in CLL progression and
therapy efficiency. The immune system is able to prevent
cancer development, either by eliminating cancer cells prior
to tumors becoming clinically detectable or by attenuating
tumor progression [2, 3]. NK and T cells may mediate
antitumor responses, particularly in the initial stages of the
disease, which may affect disease progression [4, 5]. How-
ever, advanced disease patients develop multiple immune
defects, including hypogammaglobulinemia, deregulation of
the cytokine network, or impairment of T and NK cells
function [6]. Nevertheless, targeting the immune systemmay
represent a promising therapeutic strategy in CLL. Thus,
chemotherapy is often combined with an anti-CD20 mono-
clonal antibody (rituximab) in patients with advanced stage
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disease, resulting in enhanced complete and overall response
rates. The relevant mechanism of action of rituximab is the
activation of NK cell-dependent antibody-dependent cell-
mediated cytotoxicity (ADCC) against leukemia cells [7, 8].
Lenalidomide (Revlimid; Celgene) is an immunomod-
ulatory drug that has shown a clinical effect in several
hematological disorders including myeloma [9], myelodys-
plastic syndrome (MDS) [10], and CLL [11–14]. Lenalidomide
displays a number of pharmacodynamic effects, but the main
mechanism of action is not completely known and may vary
depending on the disease. Inmultiplemyeloma, lenalidomide
exerts a direct cytotoxic effect on neoplastic plasma cells,
inhibits cell adhesion, and induces changes in the bone
marrow microenvironment [15]. In del(5q)MDS, lenalido-
mide directly affects erythroid progenitors [16]. In CLL,
significant clinical responses, including molecular complete
remissions in heavily pretreated patients, have been observed
[12, 14]. It is noteworthy that lenalidomide does not directly
induce the apoptosis of leukemic cells [17], but it regulates
critical prosurvival and angiogenic cytokines (including IL-
2, PDGF, and VEGF). Lenalidomide also stimulates antigen
presentation, proliferation, and effector activity of T cells
[18, 19] and may activate a minor cytotoxic population of
T cells known as invariant or CD1d-restricted NKT cells
[20, 21]. Furthermore, CLL cells incubated with healthy T
cells inhibit immune synapse formation, where it is restored
by lenalidomide treatment [22]. Additionally, lenalidomide
increases NK cell proliferation, which correlates with clinical
response [11, 23, 24] and augments NK cell-mediated ADCC
against tumor cells [25, 26]. Likewise, clinical responses in
CLL patients treated with lenalidomide correlated with a
tumor flare reaction [18], which appears to be characteristic
of this disease and may reflect a clinical manifestation of
the enhancement of the immunogenic potential of tumors
[14, 27].
The efficacy of lenalidomide in different malignant con-
ditions may be explained by the existence of multiple mecha-
nisms of action, different immune status, and specific patho-
genesis of the disease. Unraveling the relevant mechanism
of action is essential to optimize the treatment of patients
and to develop new therapeutic strategies.Thus, in this study,
we analyzed the mechanism of action underpinning the
therapeutic activity of lenalidomide in CLL.
2. Material and Methods
2.1. Cell Isolation and Reagents. CLL patients (𝑛 = 17) fulfill-
ing the diagnostic criteria for CLL [28] and healthy donors
(𝑛 = 10) were analyzed in this study. These patients either
were untreated or did not receive cytoreductive treatment
within 6months of the investigation.This studywas approved
by the ethics committee of our institution and informed
consent was obtained from all patients and healthy donors.
Peripheral blood mononuclear cells (PBMCs) were puri-
fied by Ficoll gradient centrifugation from freshly isolated
blood obtained from patients and donors. B cells were
further purified using EasySep Human B Cell Enrichment
Kit without CD43Depletion (Stemcell Technologies) andNK
cells were isolated fromPBMCs by using the EasySepNKCell
Enrichment kit (Stemcell Technologies). The purity of B and
NK cells (∼90 to 95%) was assessed by flow cytometry.
PBMCs or purified immune cells were cultured in com-
plete medium RPMI-1640 supplemented with 10% human
AB serum, 2mM L-glutamine, 100U/mL penicillin, and
100 𝜇g/mL streptomycin (Sigma, St. Louis, MO) at 37∘C in
5% CO
2
. Lenalidomide was obtained from Celgene and was
dissolved in dimethyl sulfoxide (DMSO), and fresh lenalido-
mide was replaced every 72 hours in cell cultures. In some
experiments, cells were treated with recombinant human IL-
2 (rhIL-2) (Peprotech), anti-human IL-2 receptor (IL-2 sR𝛼)
blocking antibody (R&D systems), or cyclosporine A (CsA)
(Sigma, St. Louis, MO). In all experiments incubation with
DMSO was used as a control.
2.2. Flow Cytometry. Diagnosis of CLL was confirmed for
each patient by flow cytometry, revealing a typical CD19+,
CD20+, CD5+, CD23+, and Ig light chain (𝜅 or 𝜆) restricted
phenotype of leukemia cells (Becton Dickinson). To deter-
mine immune cells subsets, cells were stained with anti-
CD3-FITC, anti-CD4-PerCP, anti-CD8-CFBlue, anti-CD56-
APC, and anti-CD20-PE (all from Immunostep) and anti-
CD3-PECy7 (eBioscience) and isotype-matched control con-
jugates. The populations of immune cells were defined
as follows: CD4 T cells were defined as CD3+CD4+ and
CD8 T cells as CD3+CD8+; NK cells were identified as
CD3−CD56+, NKT-like cells as CD3+CD8+CD56+, and
leukemia cells as CD5+/CD19+. CD20 expression was quan-
tified on CD5+/CD19+ cells.
To study the intracellular IL-2 production, PBMCs were
incubated in complete culturemediawithGolgiStop (BDBio-
sciences) and with monensin (a protein transport inhibitor),
for 4 hours. After that, cells were stained for surface anti-
gens and, then, incubated with a fixation/permeabilization
solution (BD Biosciences) prior to incubation with an anti-
human IL-2-PerCP-Cy5.5 antibody (BD Biosciences).
Cells undergoing apoptosis were quantified by staining
with annexin V-FITC according to the manufacturer’s proto-
col (Immunostep). Cells were analyzed in a BD FACS Canto
II cytometer and data were acquired and analyzed by using
the FACS Diva Software.
2.3. Cell Proliferation Assay. Freshly isolated PBMCs from
healthy donors and CLL patients were labeled with 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Sigma, St. Louis, MO) at 1𝜇M for 10min at 37∘C. Labeling
was stopped with 5 volumes of complete media containing
10% fetal bovine serum (FBS). After 2 washes, cells were
cultured at 2 × 106 cells/mL in complete media containing
10% of human AB serum, and 1 𝜇M lenalidomide was added
every 72 hours. After 3, 6, 9, 12, and 14 days of culture,
cells were stained for CD19, CD3, CD4, CD8, and CD56
expression. Cell division was analyzed based on the decrease
in CFSE staining, resulting from the dilution of the dye with
each cell division.
2.4. NK Cell Cytotoxic Assays. CD107a lysosome-associated
membrane protein-1 (LAMP-1) was used to measure NK-,
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Figure 1: Effect of lenalidomide on the proliferation of B cells. (a) PBMCs obtained from healthy donors (𝑛 = 10) and CLL patients (𝑛 = 17)
were labeled with CFSE and cultured with 1 𝜇M lenalidomide or DMSO for 14 days. CFSE fluorescence in B cells (gated as CD5+/CD19+) was
analyzed by flow cytometry. The histograms show a representative CLL patient and a healthy donor. (b) The figure shows the compilation of
the results obtained from healthy donors and CLL patients. Results are expressed as the fold induction of the percentage of proliferating B
cells in lenalidomide-treated cells relative to the vehicle-treated control (∗∗𝑃 < 0.01, Mann-Whitney U test).
NKT-like-, and CD8-cell cytotoxic activity. PBMCs from
healthy donors or CLL patients stimulated with 1𝜇M
lenalidomide for 14 days were incubated with target cells
at an effector : target (E : T) ratio of 5 : 1 in complete media
supplemented with human AB serum and BD GolgiStop
(BD Biosciences). As a positive control of degranulation,
PBMCs were stimulated with PMA (50 ng/mL) and iono-
mycin (1 𝜇g/mL) (both from Sigma, St. Louis, MO). The
anti-CD107a-PE antibody (BD Biosciences) was added to the
plate during the incubation. Some experiments were made in
the presence or absence of rituximab (20𝜇g/mL). After the
incubation, samples were stained for CD3, CD4, CD8, and
CD56 expression and analyzed by flow cytometry.
2.5. Statistical Analysis. Continuous variableswere compared
withMann-WhitneyU test. Correlations between continuous
variables were analyzed by Spearman correlation test. The 𝑃
values 𝑃 < 0.05 were considered statistically significant.
3. Results
3.1. Effect of Lenalidomide on Proliferation and Apoptosis of
Leukemia Cells. The effect of lenalidomide on the prolifer-
ation of B cells was initially analyzed. PBMCs from healthy
donors and CLL patients were cultured in presence of 1𝜇M
lenalidomide for 14 days and the proliferation of B cells was
assessed by CFSE assay. As shown in Figures 1(a) and 1(b),
lenalidomide did not affect the proliferation of leukemia cells,
but the proliferation of B cells from healthy donors was
significantly increased in the presence of this drug.
Next, we studied the effect of lenalidomide on the apop-
tosis of leukemia cells. PBMCs from CLL patients contain-
ing variable amounts of leukemia cells (ranging from 70%
to 95%) and nonmalignant immune cells were used. No
significant increase of apoptosis of leukemia cells from CLL
patients was observed after 48 hours of treatment with
1 𝜇M lenalidomide (not shown). Nevertheless, after 7 days of
treatment a significant effect of lenalidomide on the apoptosis
of leukemia cells was detected (Figures 2(a), 2(b), and 2(c)).
It is of note that the level of apoptosis on leukemia cells
significantly correlated with the percentage of nonmalignant
immune cells at day zero in CLL patients (𝑟 = 0.87,
𝑃 = 0.009) (Figure 2(d)). Specifically, a strong correlation
between apoptosis of leukemia cells and the percentage of
NKT-like cells (CD3+CD8+CD56+) was observed (𝑟 = 0.84,
𝑃 = 0.01) (Figure 2(e)).
3.2. Lenalidomide Enhances the Proliferation of NK Cells. In
addition to the effect observed on B cells, it is noticeable
that the percentage of NK cells significantly increased after
14 days of culture of PBMCs in the presence of lenalidomide
(Figures 3(a) and 3(b)). Moreover, such increase of NK cells
was higher in patients than in healthy donors (9.8- versus
3.4-fold induction). To analyze whether the increase of NK
cells was due to cell proliferation, PBMCs from patients
and healthy donors were CFSE-stained and cultured in the
presence of lenalidomide for 14 days, and the proliferation
of NK cells was examined by flow cytometry at days 3, 6,
9, 12, and 14. Remarkably, no effect was observed on the
proliferation of NK cells before 12 days of treatment (not
shown). Nevertheless, after 14 days, lenalidomide signifi-
cantly increased the proliferation of NK cells from both
healthy donors and CLL patients (Figures 3(c) and 3(d)),
although the level of the induction was higher in patients
than in healthy donors (2.98- versus 2.19-fold induction). In
addition, there was a significant interpatient variation in the
response to lenalidomide (ranging from no response to a 9.2-
fold induction).
Interestingly, the main subsets of NK cells (CD56bright
and CD56dim) proliferated in the presence of lenalido-
mide (not shown), although CD56bright NK cells were more
potently induced by lenalidomide than CD56dim NK cells
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Figure 2: Effect of lenalidomide on the apoptosis of leukemia cells. (a) PBMCs from CLL patients (𝑛 = 7) were cultured in the presence
of 1 𝜇M lenalidomide or DMSO for 7 days and apoptosis was analyzed by staining with annexin V. The figure shows the flow cytometric
profile of annexin V staining of leukemia cells from a representative patient after lenalidomide treatment (numbers in the dot plot represent
the percentage of cells). (b) PBMCs (ranging from 70% to 95% of leukemia cells) from CLL patients (𝑛 = 7) were cultured as detailed
in 𝑎 and apoptosis of leukemia cells was studied by annexin V staining. The scatterplot represents the percentage of apoptosis in DMSO
versus lenalidomide-treated cells. (c) The bars represent the mean and the standard deviation of the fold induction of annexin V-positive
leukemia cells (∗∗𝑃 < 0.01, Mann-Whitney U test). (d) Correlation between annexin V staining of leukemia cells and the percentage of
nonleukemia immune cells of CLL patients. (e) Correlation between annexin V labeling of leukemia cells and the percentage of NKT-like
cells (CD3+CD8+CD56+) of CLL patients.
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Figure 3: Effect of lenalidomide on NK cell proliferation. (a) Flow cytometric profile of NK cells (gated as CD3−CD56+) before and after
stimulation with 1 𝜇M lenalidomide for 14 days. One representative CLL patient and one healthy donor are shown. The numbers represent
the percentage of NK cells. (b) The figure shows the compilation of the results obtained from CLL patients (𝑛 = 17) and donors (𝑛 = 10).
Results are expressed as the fold induction of the percentage of NK cells of lenalidomide-treated cells relative to the vehicle-treated control
(∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001, Mann-WhitneyU test). (c) PBMCs labeled with CFSE were cultured with 1𝜇M lenalidomide or DMSO for 14 days
and CFSE expression was examined in NK cells (CD3−CD56+) by flow cytometry. One representative CLL patient and one healthy donor are
shown. (d) The figure shows the compilation of the results obtained from CLL patients (𝑛 = 17) and healthy donors (𝑛 = 10). Results are
expressed as the fold induction of the percentage of proliferative NK cells of lenalidomide-treated cells relative to the vehicle-treated control
(∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001, Mann-Whitney U test). (e) The figure shows the percentage of the two main subsets of NK cells (CD56dim and
CD56brigth) after the treatment with 1 𝜇M lenalidomide or DMSO for 14 days. (∗𝑃 < 0.05; ∗∗𝑃 < 0.01, Mann-Whitney U test).
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Figure 4: Effect of lenalidomide on the proliferation of T cell subsets. (a) The histograms show the CFSE expression of CD4 T cells, CD8 T
cells, andNKT-like cells before and after stimulationwith lenalidomide. PBMCswere labeled with CFSE and cultured with 1𝜇M lenalidomide
or DMSO for 14 days. CFSE expression in CD4 T cells (CD3+CD4+), CD8 T cells (CD3+CD8+), and NKT-like cells (CD3+CD8+CD56+) was
examined by flow cytometry. One representative CLL patient and one donor are shown. (b) The figure shows the compilation of the results
obtained from CLL patients (𝑛 = 17) and donors (𝑛 = 10). Results are expressed as the fold induction of the percentage of proliferative
CD4 T cells, CD8 T cells, and NKT-like cells of lenalidomide-treated cells relative to the vehicle-treated control. (∗𝑃 < 0.05; ∗∗𝑃 < 0.01;
∗∗∗
𝑃 < 0.001, Mann-Whitney U test).
(Figure 3(e)). Specifically, lenalidomide induced an inversion
of the CD56bright/CD56dim ratio from 0.82 to 1.99 in healthy
donors and from 0.33 to 1.67 in CLL patients.
3.3. Lenalidomide Stimulates the Proliferation of T Cells. We
next examined the effect of lenalidomide on the proliferation
of T cells (Figures 4(a) and 4(b)). It is of note that CD4 T cells
were the most proliferative subset of T cells in CLL patients.
The proliferation of CD4 T cell after 14 days of culture in the
presence of lenalidomide was higher in CLL patients than
in donors (2.52- versus 1.98-fold induction). Similar to NK
cells, there was a marked interindividual variability in the
proliferation of CD4 T cells; and a significant correlation
between the percentage of CD4 T cells of CLL patients after
lenalidomide treatment and the proliferation of NK cells was
observed (𝑟 = 0.49, 𝑃 = 0.04).
CD8 T cells also proliferated in response to lenalidomide,
but the level of induction was higher in donors than in
patients (7.03- versus 1.72-fold induction) (Figures 4(a) and
4(b)). Specifically, CD8proliferated in 100%of healthy donors
and 66% of CLL patients. Similar results were obtained with
NKT-like cells, a subset of CD8T cells (Figures 4(a) and 4(b)).
3.4. Induction of IL-2 Production by CD4 T Cells Is Required
for the Enhancement of NK Cell and NKT-Like Cell Pro-
liferation by Lenalidomide. To unravel the mechanism of
action underlying the induction of NK cell proliferation
observed, we analyzed whether lenalidomide has a direct
or an indirect effect on NK cell proliferation by compar-
ing the effect of lenalidomide on whole PBMCs versus
purified NK cells. The depletion of non-NK immune cells
by negative selection completely abrogated the induction
of NK cell proliferation in both CLL patients and donors
(Figure 5(a)), suggesting that the effect of lenalidomide on
NK cell proliferation was indirect. We next examined the
effect of lenalidomide on the production of IL-2 by immune
cells by intracellular staining and flow cytometry. As shown
in Figure 5(b), lenalidomide treatment significantly induced
the production of IL-2 by CD4 T cells. Furthermore, NK cell
proliferation was abrogated in the presence of an anti-IL-2
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Figure 5: Production of IL-2 by CD4T cells is required for lenalidomide-increasedNK andNKT-like cells proliferation. (a)Whole PBMCs or
purified NK cells (>95% of purity) from the same individual (𝑛 = 4) were labeled with CFSE and cultured with 1 𝜇M lenalidomide or DMSO
for 14 days (in the absence of recombinant IL-2, w/o).The proliferation of NK cells (CD3−CD56+) was assessed by flow cytometry.The figure
shows the cytometric profile of NK cells (gated as CD3−CD56+) before and after the stimulation with lenalidomide. The numbers represent
the percentage of NK cells. The histograms represent the expression of CFSE in NK cells from one representative donor. (b) PBMCs from
healthy donors (𝑛 = 4) and CLL patients (𝑛 = 4) were cultured in the presence of lenalidomide for 14 days and the intracellular production of
IL-2 by CD4 T cells (CD3+CD4+) was analyzed by flow cytometry. The bars represent the mean and the standard deviation of the percentage
of IL-2-producing CD4 T cells (∗𝑃 < 0.05, Mann-Whitney U test). (c) PBMCs from healthy donors (𝑛 = 4) and CLL patients (𝑛 = 4) were
stained with CFSE and cultured with DMSO, IL-2 (50U/mL), or lenalidomide (1 𝜇M) in presence or absence of cyclosporine A (CsA) (1𝜇M)
or as anti-IL-2 blocking antibody (15 𝜇g/mL) for 14 days. PBMCs treated with IL-2 (50U/mL) were used as a positive control of proliferation.
Baseline peaks of CFSE are the same as in Figures 3(c) and 4(a). The expression of CFSE on NK cells and NKT-like cells (CD3+CD8+CD56+)
was analyzed by flow cytometry. One representative healthy donor and one CLL patient are shown.
receptor blocking antibody or cyclosporine A, indicating that
the production of IL-2 was required for the proliferation of
NK cells (Figure 5(c)). Similarly, IL-2 was also involved in
the proliferation of NKT-like cells. Finally, we demonstrated
that NK and NKT-like cell proliferation was induced by the
treatment of PBMCs obtained from both patients and donors
with IL-2 (Figure 5(c)). Overall, these results indicate that
the production of IL-2 by CD4 T cells is required for the
induction of the proliferation of NK and NKT-like cells by
lenalidomide. It is worth mentioning that IL-2 was also able
to induce the proliferation of NK cells obtained from CLL
patients who did not respond to lenalidomide treatment.
3.5. Lenalidomide Increases NK Cell-Mediated Natural Cyto-
toxicity and ADCC against Primary Leukemia Cells. First,
the effect of lenalidomide on the expression of the main NK
cell activating receptors was studied. To this end, PBMCs
from patients and controls were incubated with lenalidomide
for 7 days and the expression of NKG2D, DNAM1, NKp30,
NKp44, and NKp46 was analyzed by flow cytometry. These
experiments showed a significant increase in the expression
of NKp30 on NK cells of CLL patients after lenalidomide
treatment (Figure 6).
Next, we assessed whether lenalidomide modulates the
cytotoxic activity of NK cells against purified leukemia cells.
PBMCs from healthy donors incubated with lenalidomide or
DMSO for 14 days were cocultured with purified leukemia
cells obtained from CLL patients for 4 hours. Lenalidomide
treatment significantly increased the cytotoxic activity of
NK cells (1.5-fold induction) and NKT-like cells (2-fold
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Figure 6: Effect of lenalidomide on the expression of NK cell
activating receptors. PBMCs from healthy donors and CLL patients
were treated with 1 𝜇M lenalidomide or DMSO for 7 days and the
expression of NKG2D, DNAM-1, NKp30, NKp44, and NKp46 on
NK cells (CD3−CD56+) was analyzed by flow cytometry. The figure
shows the compilation of the results obtained from patients (𝑛 = 4)
and donors (𝑛 = 3) before and after lenalidomide treatment. The
bars represent the mean and standard deviation of the MFI.
induction) against primary leukemia cells (Figures 7(a) and
7(b)), but no effect was observed on CD8 T cells (shown
in Figure 7(a)). Similar results were obtained using IL-2 or
IL-15 treatment (not shown). The cytotoxic activity was not
further increased when leukemia cells were also treated with
lenalidomide, suggesting that the major effect of lenalido-
mide was exerted on the activity of immune cells.
The recognition of leukemia cells by NK cells may be
increased with the use of antileukemic monoclonal antibod-
ies [7, 8]. Thus, treatment of leukemia cells with rituximab
(anti-CD20) in the absence of lenalidomide significantly
increased the cytotoxic activity of NK (4.3-fold) and NKT-
like cells (1.7-fold) against primary leukemia cells (Fig-
ures 7(a) and 7(b)). Moreover, lenalidomide significantly
increased the rituximab-mediated cytotoxic activity of NK
cells (1.5-fold) and NKT-like cells (1.6-fold) against leukemia
cells (Figures 7(a) and 7(b)), but no effect was observed on
CD8 T cells (shown in Figure 7(a)).
To characterize the underlying mechanism involved in
the cooperative effect between lenalidomide and rituximab,
we analyzed the effect of lenalidomide on CD20 expression
on leukemia cells (CD5+/CD19+) after 2, 7, and 14 days of
treatment. No clear effect on CD20 expression was observed
after 48 hours of treatment, but it is noteworthy that a
significant increase of CD20 expression was observed after 7
and 14 days of treatment (Figures 7(c) and 7(d)).
Our findings suggest that lenalidomide indirectly pro-
motes the proliferation and cytotoxic activity of NK and
NKT-like cells against primary leukemia cells. Additionally,
lenalidomide induces ADCC to rituximab-treated leukemia
cells of CLL patients. Overall, these data indicate that NK and
NKT-like cells are relevant mediators of lenalidomide-driven
apoptosis of leukemia cells in CLL.
4. Discussion
The activation of the antileukemic immune response rep-
resents a promising therapeutic option in CLL, particularly
for relapsed patients. In this regard, lenalidomide is an
immunomodulatory drug with significant therapeutic activ-
ity in CLL. However, lenalidomide has a pleiotropic activity
and the relevant mechanism of action responsible for its
therapeutic activity has not been well defined [11–14]. Our
study indicates that the antileukemic activity of lenalidomide
is not due to the direct cytotoxicity against leukemia cells,
but rather it may imply indirect mechanisms through the
activation of nonmalignant immune cells, particularly NK
and CD4 T cells.
Our study shows a pleiotropic effect of lenalidomide
on different types of immune cells including NK, T, and B
cells. It is noticeable that, unlike normal B cells, transformed
B cells do not proliferate in the presence of lenalidomide,
suggesting that leukemia cells lose the capacity to respond
to lenalidomide. Nevertheless our data suggest that NK and
CD4 T cells may play a relevant role in the antileukemic
effect of lenalidomide in CLL. Thus, lenalidomide was able
to induce the proliferation of NK cells, and this effect was
higher in CLL patients than in healthy donors. In agreement
with our data, the NK cell number in patients was increased
by lenalidomide treatment in vivo and pretreatment levels
of NK cells correlated with the response to therapy in CLL
[11, 23, 24]. Additionally, we observed that lenalidomide has
an important effect on the proliferation of T cells, particularly
CD4 T cells. The proliferation of CD4 T cells in response to
lenalidomide treatment was also higher in patients than in
healthy donors, and the percentage of CD4 T cells of CLL
patients after lenalidomide treatment significantly correlated
with the proliferation of NK cells. Additionally, the depletion
of T cells abrogated the proliferation of NK cells suggesting
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Figure 7: Lenalidomide enhanced natural cytotoxicity and ADCC against primary leukemia cells. (a) PBMCs from healthy donors (𝑛 = 4)
and purified leukemia cells (>90% of purity) obtained from CLL patients (𝑛 = 4) were treated with 1 𝜇M lenalidomide or DMSO for 14
days. Lenalidomide and DMSO-stimulated PBMCs were cocultured with both lenalidomide and DMSO-stimulated leukemia cells at 5 : 1
E : T ratio in the presence or absence of rituximab (20𝜇g/mL). The expression of CD107a was evaluated in NK cells (CD3−CD56+), CD8 T
cells (CD3+CD8+), and NKT-like cells (CD3+CD8+CD56+) by flow cytometry. Representative dot plots showing CD107a expression on CD8,
NKT-like, and NK cells of one representative experiment are shown. The numbers represent the percentage of CD107a+ cells for each subset
analyzed. (b) The figure shows the compilation of the results obtained from patients and donors. The bars represent the mean and standard
deviation of the percentage of CD107a+ NK cells and NKT-like cell (∗𝑃 < 0.05; Mann-Whitney U test). (c) The histograms show the analysis
of CD20 expression in leukemia cells after 14 days of lenalidomide treatment of a representative patient. Numbers in the histogram are the
mean fluorescence intensity (MFI). (d) PBMCs from CLL patients (𝑛 = 4) were cultured with lenalidomide (1𝜇M) for 2, 7, and 14 days and
the expression of CD20 was analyzed on B cells (gated as CD5+/CD19+) by flow cytometry. Results are expressed as the fold induction of
CD20 MFI in lenalidomide-treated cells relative to the vehicle-treated control (∗𝑃 < 0.05; Mann-Whitney U test).
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a potential link between both cell types. It has been reported
that lenalidomide facilitates the nuclear translocation of
NFAT and AP-1, via activation of PI3K signaling, which
results in IL-2 secretion by T cells [29]. Accordingly, our
experiments show that the proliferation of NK and NKT-like
cells is mediated by the production of IL-2 by CD4 T cells in
CLL.Thus, the blockade of IL-2 activity completely abrogated
the proliferation of NK and NKT-like cells. However, a
remarkable observation in our study is the existence of a
significant interindividual variation in the NK cell response
among patients. It is worth mentioning that, in those CLL
patients who did not respond to lenalidomide, IL-2 was able
to induce the proliferation and the cytotoxic activity of NK
cells, suggesting that the level of induction of IL-2 production
by CD4 T cells by lenalidomide may be involved in this
marked variation of response. The analysis of the therapeutic
consequences of this variation and the potential predictive
value of the in vitro analysis of NK cell proliferation deserves
further investigation.
We observed that lenalidomide enhanced NK cell-
mediated natural cytotoxicity against leukemia cells. This
effect was mainly due to the activation of immune cells, since
no further effect was achieved when leukemia cells were also
treatedwith lenalidomide. Lenalidomide treatment increased
the expression of NKp30 on NK cells from CLL patients,
suggesting a role of this receptor in the increase of NK cell
cytotoxicity observed in response to lenalidomide. It is also
remarkable, but not unexpected, that lenalidomide had only
amodest effect on promoting the antileukemic activity of NK
cells against primary leukemia cells. In fact, leukemia cells
express low levels of ligands of NK cell activating receptors,
probably due to immune evasion mechanisms, being highly
resistant to NK cell-mediated lysis [1, 30]. To increase the
cytotoxic activity against leukemia cells it is necessary to
favor the recognition of leukemia cells by NK and NKT-
like cells. In line with this idea, lenalidomide is an attractive
agent for combination with rituximab [25]. Our experiments
showed a synergistic effect of lenalidomide with rituximab
in promoting ADCC against leukemia cells, and this effect
is supported by the fact that lenalidomide upregulated CD20
expression on leukemia cells. Overall, our findings provide a
support for the combined use of lenalidomide with rituximab
in the treatment of CLL patients and suggest that other
treatments that increase the immunogenicity of tumor cells,
for instance, by inducing the expression of ligands of NK
cell receptors on leukemia cells such as histone deacetylase
inhibitors [30], may be an attractive therapeutic strategy to
be combined with lenalidomide.This clearly warrants further
investigation.
In conclusion, our study indicates that the activation
of CD4 T and NK cells is a key process underlying the
therapeutic effect of lenalidomide in CLL, thus providing a
rational support for optimizing and improving the efficacy of
lenalidomide treatment in CLL patients.
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